0001213900-21-015712.txt : 20210316 0001213900-21-015712.hdr.sgml : 20210316 20210316161833 ACCESSION NUMBER: 0001213900-21-015712 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210316 DATE AS OF CHANGE: 20210316 EFFECTIVENESS DATE: 20210316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-392456 FILM NUMBER: 21745931 BUSINESS ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 551-578-2261 MAIL ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 D 1 primary_doc.xml X0708 D LIVE 0001711786 Hoth Therapeutics, Inc. 1 ROCKEFELLER PLAZA SUITE 1039 NEW YORK NY NEW YORK 10020 646-756-2997 NEVADA None None Corporation true 2017 Robb Knie 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Executive Officer Director Chief Executive Officer and President David Briones 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Executive Officer Chief Financial Officer Stefanie Johns 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Executive Officer Chief Scientific Officer David Sarnoff 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Director Vadim Mats 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Director Graig Springer 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Director Wayne Linsley 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Director Pharmaceuticals Decline to Disclose 06b false 2021-03-10 false true true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE NEW YORK NY NEW YORK 10020 IL ILLINOIS NJ NEW JERSEY NY NEW YORK false 15000000 15000000 0 false 13 1050000 0 Represents a fee of 7% of the gross proceeds from the sale of securities. Excludes (i) a management fee of $150,000; (ii) non-accountable expenses of $35,000; (iii) accountable expenses of $50,000; and (iv) 379,747 placement agent warrants. 0 false Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer 2021-03-16